Author(s)
Georgiadis A1, Theodoridou A2, Vounotrypidis P3, Zisopoulos D4, Kallitsakis I5, Kandyli A6, Migkos M7, Bournazos I8, Sidiropoulos P9, Efstathiou M10, Athanassiou P11, Haratsis I12, Petrikkou E12, Vassilopoulos D13
1Private Practice, Ioannina, Greece, 2Private .Practice, Thessaloniki, Greece, 3Private Practice., Thessaloniki, Greece, 4Private Practice, Thessaloniki, Greece, 5Private Practice, Chania, Greece, 6Private Practice, Athens, Greece, 7Private Practice, Florina, Greece, 8Private Practice., Athens, Greece, 9Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Crete, Greece, 10Private Practice,, Thessaloniki, Greece, 11Rheumatology Department, Agios Pavlos General Hospital, Thessaloniki, Greece, 12Medical Affairs, Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial SA, Alimos, Greece, 132nd Department of Internal Medicine and Laboratory, Hippokration General Hospital, Athens, Greece
OBJECTIVES : To assess the real-world effectiveness of golimumab and its impact on patient-reported outcomes in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondylarthritis (axSpA). METHODS : GO-BEYOND is a prospective, 18-month study, in patients with active RA, PsA or axSpA and an inadequate response/intolerability to 1 TNFα inhibitor, who are considered for golimumab treatment. Primary objective is the proportion of patients attaining low disease activity (LDA) in RA (by Disease Activity Score for 28 joints with C-reactive protein [DAS28-CRP]), minimal disease activity (MDA) in PsA (by MDA criteria) and moderate disease activity in axSpA (by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and inactive disease by Ankylosing Spondylitis Disease Activity Score [ASDAS]), at 6 months. Other objectives include the assessment of work productivity/activity impairment (by Work Productivity and Activity Impairment Questionnaire for RA) and quality of life (QoL; by EQ-5D-3L), at 3/6/12/18 months. This interim analysis presents results for patients who participated in the study for 6 months (cut-off date:28/02/2019). Per-indication statistical comparisons were not performed due to small sample size. RESULTS : Thirty-six patients (RA:13; PsA:10; axSpA:13) with moderate disease activity in all 3 indications were included. Following 6 months on golimumab, patients’ disease activity was improved; 81.8% of patients with RA achieved LDA; 11.1% of patients with PsA achieved MDA; of patients with axSpA, 30.8% achieved moderate disease activity by BASDAI and 38.5% inactive disease by ASDAS. Mean±sd score changes from baseline to 3 and 6 months in work productivity loss were -18.3±26.0, -20.8±29.0, and in activity impairment -27.1±28.8, -33.7±31.2, respectively. Mean±sd EQ-5D-3LUK index scores at baseline, 3 and 6 months were: 0.406±0.192, 0.641±0.270 and 0.754±0.279, respectively. CONCLUSIONS : In this interim analysis, patients with active RA, PsA or axSpA showed improvements in disease activity, work productivity/activity impairment and QoL after 6 months of golimumab treatment.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PBI87
Topic
Economic Evaluation, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs
Disease
Systemic Disorders/Conditions
